Overview of Neutralizing Antibodies and Their Potential in COVID-19

José Javier Morales-Núñez; José Francisco Muñoz-Valle; Paola Carolina Torres-Hernández; Jorge Hernández-Bello

doi:10.3390/vaccines9121376

Overview of Neutralizing Antibodies and Their Potential in COVID-19

Vaccines (Basel). 2021 Nov 23;9(12):1376. doi: 10.3390/vaccines9121376.

Authors

José Javier Morales-Núñez¹, José Francisco Muñoz-Valle¹, Paola Carolina Torres-Hernández², Jorge Hernández-Bello¹

Affiliations

¹ Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.
² Immunology Laboratory, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.

Abstract

The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity against SARS-CoV-2, vaccine efficacy, and humoral protective response longevity, as well as supporting donor selection criteria for convalescent plasma therapy. In the current manuscript, we review the essential concepts of NAbs, examining their concept, mechanisms of action, production, and the techniques used for their detection; as well as presenting an overview of the clinical use of antibodies in COVID-19.

Keywords: COVID-19; SARS-CoV-2; monoclonal antibodies; neutralization assays; neutralizing antibodies.

Publication types

Review